- Home
- HSBC vs MRK Comparison
HSBC vs MRK Comparison
Compare HSBC & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSBC | MRK |
|---|---|---|
| Founded | 1865 | 2000 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.5B | 268.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HSBC | MRK |
|---|---|---|
| Price | $85.10 | $107.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | N/A | ★ $114.86 |
| AVG Volume (30 Days) | 1.6M | ★ 11.3M |
| Earning Date | 02-18-2026 | 02-03-2026 |
| Dividend Yield | ★ 3.91% | 3.14% |
| EPS Growth | N/A | ★ 58.08 |
| EPS | 0.93 | ★ 7.56 |
| Revenue | $57,976,000,000.00 | ★ $64,235,000,000.00 |
| Revenue This Year | $13.11 | $1.97 |
| Revenue Next Year | $1.87 | $4.71 |
| P/E Ratio | $90.31 | ★ $14.32 |
| Revenue Growth | 0.01 | ★ 1.68 |
| 52 Week Low | $45.66 | $73.31 |
| 52 Week High | $84.24 | $112.90 |
Technical Indicators
Market Signals| Indicator | HSBC | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 77.09 | 52.47 |
| Support Level | $83.40 | $106.93 |
| Resistance Level | $84.24 | $111.97 |
| Average True Range (ATR) | 0.74 | 2.66 |
| MACD | 0.06 | -0.59 |
| Stochastic Oscillator | 94.72 | 9.05 |
Price Performance
Historical ComparisonAbout HSBC HSBC Holdings plc.
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and 40 million customers worldwide. It operates in more than 50 countries with more than 200,000 full-time staff. The United Kingdom and Hong Kong are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).